Clinical Pharmacokinetics of Inhaled Budesonide

被引:0
|
作者
Richard Donnelly
J. Paul Seale
机构
[1] University of Nottingham,School of Medical & Surgical Sciences
[2] University of Sydney,Department of Pharmacology
[3] University of Nottingham,Division of Vascular Medicine
来源
Clinical Pharmacokinetics | 2001年 / 40卷
关键词
Budesonide; Fluticasone Propionate; Beclomethasone Dipropionate; Mometasone Furoate; Lung Deposition;
D O I
暂无
中图分类号
学科分类号
摘要
The corticosteroid budesonide is a 1: 1 racemic mixture of 2 epimers, (22R)-and (22S)-, and is available in 3 different inhaled formulations for the management of asthma: a pressurised metered dose inhaler (pMDI), a dry powder inhaler (DPI) and a solution for nebulised therapy. Inhaled corticosteroids such as budesonide reach the systemic circulation either by direct absorption through the lungs (a route that is much more important than previously recognised) or via gastrointestinal absorption of drug that is inadvertently swallowed. Although the pharmacokinetics of budesonide have been extensively investigated following oral and intravenous administration, relatively few studies have defined the systemic disposition of budesonide after inhalation.
引用
收藏
页码:427 / 440
页数:13
相关论文
共 50 条
  • [41] Safety of Inhaled Budesonide Clinical Manifestations of Systemic Corticosteroid-Related Adverse Effects
    Christensson, Camilla
    Thoren, Anders
    Lindberg, Bengt
    DRUG SAFETY, 2008, 31 (11) : 965 - 988
  • [42] A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma
    Evans, DJ
    Taylor, DA
    Zetterstrom, O
    Chung, F
    OConnor, BJ
    Barnes, PJ
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (20): : 1412 - 1418
  • [43] Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
    Price, DB
    Hernandez, D
    Magyar, P
    Fiterman, J
    Beeh, KM
    James, IG
    Konstantopoulos, S
    Rojas, R
    van Noord, JA
    Pons, M
    Gilles, L
    Leff, JA
    THORAX, 2003, 58 (03) : 211 - 216
  • [44] Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials
    Roberts, Jessica K.
    Stockmann, Chris
    Dahl, Mar Janna
    Albertine, Kurt H.
    Egan, Edmund
    Lin, Zhenjian
    Reilly, Christopher A.
    Ballard, Philip L.
    Ballard, Roberta A.
    Ward, Robert M.
    CURRENT CLINICAL PHARMACOLOGY, 2016, 11 (01): : 53 - 61
  • [46] Effect of inhaled formoterol and budesonide on exacerbations of asthma
    Salvi, S
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (15): : 1072 - 1072
  • [47] INHALED BUDESONIDE AEROSOLS IN TREATMENT OF CHILDHOOD ASTHMA
    PHANICHYAKARN, P
    WONG, ECK
    ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 1988, 6 (02): : 111 - 115
  • [48] INHALED BUDESONIDE FOR MAINTENANCE TREATMENT OF PULMONARY SARCOIDOSIS
    SELROOS, O
    LOFROOS, AB
    PIETINALHO, A
    NIEMISTO, M
    RISKA, H
    SARCOIDOSIS, 1994, 11 (02): : 126 - 131
  • [49] INHALED BUDESONIDE FOR THE PREVENTION OF ACUTE MOUNTAIN SICKNESS
    Chen Guozhu
    Huang Lan
    HEART, 2013, 99 : E281 - E281
  • [50] Inhaled Budesonide in the Treatment of COVID-19
    Kluge, S.
    Nitschmann, S.
    Scherer, M.
    INTERNIST, 2021, 62 (08): : 887 - 889